preeclampsia
Progenity to Close Genetics Lab as Focus Shifts to Therapeutics
The firm will no longer offer its Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, or Resura Prenatal Test.
Progenity Q4 Revenues Fall 30 Percent on COVID-19 Effect
The firm's revenue decrease was largely driven by a decline in testing volumes due to the COVID-19 pandemic, it said.
Progenity Projects 2021 Revenue Growth of Up to 30 Percent
The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
Progenity Q3 Revenues Increase 38 Percent
The company performed 84,067 total tests in Q3 but missed the analysts' average estimates on the top and bottom lines.
BTIG Initiates Coverage of Progenity With Buy Rating
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.
Jun 10, 2020
PerkinElmer Preeclampsia Kit Gets CE-IVD Mark
Apr 18, 2019
Mar 26, 2019
May 24, 2018
Mar 6, 2018